Talphera Q4 net loss widens 101.71% to USD 3.8 million on cash and investments of USD 20 million

Reuters03-23

Talphera Q4 net loss widens 101.71% to USD 3.8 million on cash and investments of USD 20 million

Talphera published a press release reporting fourth-quarter and full-year 2025 financial results and a corporate update.
Fourth-quarter net loss attributable to common shareholders was USD 3.8 million, widening 103.2% year over year.
Combined R&D and SG&A expenses in the fourth quarter were USD 3.5 million, up 16.7%, driven primarily by higher costs tied to Niyad development and certain G&A expenses.
Cash and investments totaled USD 20.4 million at Dec. 31, 2025, and Talphera said it closed a USD 4.1 million financing tranche after reaching 50% enrollment (35 of 70 patients) in the NEPHRO CRRT study.
For 2026, cash operating expenses excluding stock-based compensation are expected to be USD 17.0 million to USD 18.0 million, reflecting costs to finalize the NEPHRO CRRT registration trial and related CMC expenses and validation batches ahead of a planned FDA PMA filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Talphera Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603230830PR_NEWS_USPR_____SF16017) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621705515?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621705515","market":"fut","top_or_hot":-1,"title":"Talphera Q4 net loss widens 101.71% to USD 3.8 million on cash and investments of USD 20 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Talphera Q4 net loss widens 101.71% to USD 3.8 million on cash and investments of USD 20 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Talphera published a press release reporting fourth-quarter and full-year 2025 financial results and a corporate update.\n        </li>\n<li>\n          Fourth-quarter net loss attributable to common shareholders was USD 3.8 million, widening 103.2% year over year.\n        </li>\n<li>\n          Combined R&amp;D and SG&amp;A expenses in the fourth quarter were USD 3.5 million, up 16.7%, driven primarily by higher costs tied to Niyad development and certain G&amp;A expenses.\n        </li>\n<li>\n          Cash and investments totaled USD 20.4 million at Dec. 31, 2025, and Talphera said it closed a USD 4.1 million financing tranche after reaching 50% enrollment (35 of 70 patients) in the NEPHRO CRRT study.\n        </li>\n<li>\n          For 2026, cash operating expenses excluding stock-based compensation are expected to be USD 17.0 million to USD 18.0 million, reflecting costs to finalize the NEPHRO CRRT registration trial and related CMC expenses and validation batches ahead of a planned FDA PMA filing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TLPH\">Talphera Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603230830PR_NEWS_USPR_____SF16017) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Talphera Q4 net loss widens 101.71% to USD 3.8 million on cash and investments of USD 20 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTalphera Q4 net loss widens 101.71% to USD 3.8 million on cash and investments of USD 20 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Talphera Q4 net loss widens 101.71% to USD 3.8 million on cash and investments of USD 20 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Talphera published a press release reporting fourth-quarter and full-year 2025 financial results and a corporate update.\n        </li>\n<li>\n          Fourth-quarter net loss attributable to common shareholders was USD 3.8 million, widening 103.2% year over year.\n        </li>\n<li>\n          Combined R&amp;D and SG&amp;A expenses in the fourth quarter were USD 3.5 million, up 16.7%, driven primarily by higher costs tied to Niyad development and certain G&amp;A expenses.\n        </li>\n<li>\n          Cash and investments totaled USD 20.4 million at Dec. 31, 2025, and Talphera said it closed a USD 4.1 million financing tranche after reaching 50% enrollment (35 of 70 patients) in the NEPHRO CRRT study.\n        </li>\n<li>\n          For 2026, cash operating expenses excluding stock-based compensation are expected to be USD 17.0 million to USD 18.0 million, reflecting costs to finalize the NEPHRO CRRT registration trial and related CMC expenses and validation batches ahead of a planned FDA PMA filing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TLPH\">Talphera Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603230830PR_NEWS_USPR_____SF16017) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL39fFD9:1","article_id":"2621705515","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621705515","pubTimestamp":1774269163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Talphera published a press release reporting fourth-quarter and full-year 2025 financial results and a corporate update.Fourth-quarter net loss attributable to common shareholders was USD 3.8 million, widening 103.2% year over year.Combined R&D and SG&A expenses in the fourth quarter were USD 3.5 million, up 16.7%, driven primarily by higher costs tied to Niyad development and certain G&A expenses.Cash and investments totaled USD 20.4 million at Dec. 31, 2025, and Talphera said it closed a USD 4.1 million financing tranche after reaching 50% enrollment  in the NEPHRO CRRT study.For 2026, cash operating expenses excluding stock-based compensation are expected to be USD 17.0 million to USD 18.0 million, reflecting costs to finalize the NEPHRO CRRT registration trial and related CMC expenses and validation batches ahead of a planned FDA PMA filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TLPH":"Talphera Inc."},"translate_title":"Talphera第四季度净亏损扩大101.71%至380万美元，现金和投资为2000万美元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLPH":0.9},"content_text":"Talphera Q4 net loss widens 101.71% to USD 3.8 million on cash and investments of USD 20 million\n    \n\n\n          Talphera published a press release reporting fourth-quarter and full-year 2025 financial results and a corporate update.\n        \n\n          Fourth-quarter net loss attributable to common shareholders was USD 3.8 million, widening 103.2% year over year.\n        \n\n          Combined R&D and SG&A expenses in the fourth quarter were USD 3.5 million, up 16.7%, driven primarily by higher costs tied to Niyad development and certain G&A expenses.\n        \n\n          Cash and investments totaled USD 20.4 million at Dec. 31, 2025, and Talphera said it closed a USD 4.1 million financing tranche after reaching 50% enrollment (35 of 70 patients) in the NEPHRO CRRT study.\n        \n\n          For 2026, cash operating expenses excluding stock-based compensation are expected to be USD 17.0 million to USD 18.0 million, reflecting costs to finalize the NEPHRO CRRT registration trial and related CMC expenses and validation batches ahead of a planned FDA PMA filing.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Talphera Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603230830PR_NEWS_USPR_____SF16017) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621705515","isCrawlerRequest":true}